In this Q&A, Dr. Luis E. Raez and nurse practitioner Beth Sandy discuss recently reported MARIPOSA data in the context of current standard of care and provide best practices for therapeutic selection and patient education. Read more
By Nathan Pennell, MD, PhD Posted: April 16, 2020 It’s an exciting time to be a thoracic oncologist. We live in an era of unprecedented discovery in medicine—and in oncology […] Read more
By Kara Nyberg, PhD Posted: April 16, 2020 After decades of failed clinical trials and persistently dismal lung cancer survival outcomes, the 2010s breathed new life into the beleaguered field […] Read more
Posted: April 16, 2020 As we know, molecular marker identification allows for more rational use of existing therapies. When markers can be identified more effectively and quickly, patient care advances. […] Read more
By Mizuki Nishino, MD, MPH Posted: April 16, 2020 Dr. Mizuki Nishino Artificial intelligence (AI) approaches have emerged as promising tools to address important unmet needs across different specialties in […] Read more
By Corey J. Langer, MD, ILCN Editor Posted: April 16, 2020 Dr. Corey Langer Michele Carbone MD, Ph.D and colleagues have penned a far-ranging editorial, now published online in the […] Read more
By Youquan Li, MD, FRCR, and Andrea Bezjak, MDCM, MSc, FRCPC Posted: February 12, 2020 Targeted agents including TKIs of EGFR, ALK, and ROS1 have significantly improved the outcomes of […] Read more
Posted: February 12, 2020 Ravi Salgia, MD, PhD, is the Arthur & Rosalie Kaplan Endowed Chair in Medical Oncology and the associate director for clinical sciences at City of Hope’s […] Read more
By Alexander Drilon, MD Posted: February 12, 2020 The receptor tyrosine kinases TRKA/B/C are encoded by the genes NTRK1/2/3. TRK fusions are oncogenic drivers of various adult and pediatric cancers. […] Read more
Posted: February 12, 2020 Edgardo S. Santos Castillero, MD, FACP, is an IASLC Lung Cancer News Editorial Group Member and served as a co-chair on the expert panel that developed […] Read more
By Neal Ready, MD, PhD Posted: February 12, 2020 Dr. Neal Ready Programmed death receptor (PD-1) checkpoint monoclonal antibody therapy has proven a major advancement in the management of advanced […] Read more